Genmab A/S has secured a third commercial deal involving its new bispecific antibody technology, this time with Janssen Biotech Inc (Johnson & Johnson). The deal includes a $3.5 million upfront payment and milestones of $175 million. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
